Company news
China Resources Jiangzhong Pharmaceutical Co., Ltd. Class A (SSE:600750) news
China Resources Jiangzhong Pharmaceutical Co., Ltd. Class A news releases on 6ix. Latest, Sep 11, 2026: "CHINA RESOURCES JIANGZHONG PHARMACEUTICAL CO.…
View China Resources Jiangzhong Pharmaceutical Co., Ltd. Class A →
Press releases & updates
"CHINA RESOURCES JIANGZHONG PHARMACEUTICAL CO., LTD."Announcement on Obtaining the Proprietary Chinese Medicine Registration Certificate in Macao for Jianwei Xiaoshi Tablet
September 10, 2026
"CHINA RESOURCES JIANGZHONG PHARMACEUTICAL CO., LTD."Announcement on Implementation of Dividend Distribution for the First Half of 2026
September 2, 2026
"CHINA RESOURCES JIANGZHONG PHARMACEUTICAL CO., LTD."Announcement on the Profit Distribution Plan for the First Half of 2026
August 21, 2026
"CHINA RESOURCES JIANGZHONG PHARMACEUTICAL CO., LTD."Announcement on Convening the 2026 Semi-annual Performance Briefing
August 18, 2026
"CHINA RESOURCES JIANGZHONG PHARMACEUTICAL CO., LTD."Announcement on Implementation of Repurchase and Cancellation of Restricted Shares under the Equity Incentive Plan
July 13, 2026
Announcement on Implementation of Dividend Distribution for 2025
June 12, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
June 5, 2026
Announcement on Lifting of Sales Restrictions and Listing in the 3rd Lifting Period of Reserved Granted Portion under the 2021 Restricted Stock Incentive Plan
May 25, 2026
Announcement on Conducting Deposit Business with China Resources Bank of Guangdong and Related Party Transactions
May 15, 2026
Announcement on Attending the 2026 Online Collective Reception Day for Investors of Listed Companies in Jiangxi Jurisdiction
May 12, 2026
Announcement on Achievements of Vesting Conditions for the 3rd Unlocking Period of Reserved Grant Part under 2021 Restricted Stock Incentive Plan
April 24, 2026
Indicative Announcement on the Publication of the 2025 Performance Announcement by CR Pharmaceutical Group Co., Ltd., an Indirectly Controlled Company of the Controlling Shareholder
March 25, 2026
Announcement on Using Idle Self-owned Funds for Entrusted Wealth Management
March 19, 2026
Announcement on the Reserved Grant Results of the 2nd Phase Restricted Stock Incentive Plan
February 13, 2026
Announcement on Resolutions of the 12th Meeting of the 10th Board of Directors
February 3, 2026
Announcement on Implementation of Change of the Company's Stock Abbreviation
January 26, 2026
Announcement on Preliminary Earnings Estimate for 2025
January 23, 2026
Indicative Announcement on Changing Company Name, Completing Industrial and Commercial Change Registration and Changing Stock Abbreviation
January 19, 2026
Announcement on Progress in Participating in the Establishment of Double-Crane Pharmaceutical Industry Investment Fund Phase II and Completion of Fund Filing
January 5, 2026
Announcement on Resolutions of the 11th Meeting of the 10th Board of Directors
December 29, 2025
Announcement on Changing Company Name and Stock Abbreviation, Changing Registered Capital, Canceling Board of Supervisors, Amending the "Articles of Association" and Formulating and Revising Corporate Governance Systems
December 12, 2025
Announcement on Lifting of Sales Restrictions and Listing in the 3rd Lifting Period of Initially Granted Portion under the 2021 Restricted Stocks Incentive Plan
November 24, 2025
江中药业关于变更审计项目合伙人、签字会计师及质量控制复核人的公告
November 18, 2025
Announcement on Progress in Participating in the Establishment of Double-Crane Pharmaceutical Industry Investment Fund Phase II and Related Party Transactions
October 28, 2025
Announcement on the Implementation of Repurchase and Cancellation of Equity Incentive Restricted Stocks
October 27, 2025
Announcement on Resolutions of the 8th Meeting of the 10th Board of Supervisors
October 24, 2025
Announcement on Convening the Q3 2025 Performance Briefing
October 21, 2025
Announcement on Implementation of Semi-annual Dividend Distribution for 2025
September 26, 2025
Indicative Announcement on Equity Change of Controlling Shareholder and Its Persons Acting in Concert Reaching 1% Scale
September 18, 2025
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025
September 8, 2025
Announcement on Notifying Creditors of Repurchase and Cancellation of Partial Restricted Stocks
August 21, 2025
Announcement on Participating in the Establishment of Double-Crane Pharmaceutical Industry Investment Fund Phase II and Related Party Transactions
July 17, 2025
Announcement on Implementation of Dividend Distribution for 2024
June 13, 2025
Announcement on Results of Initial Granting under Phase II Restricted Stock Incentive Plan
June 9, 2025
Announcement on Lifting of Sales Restrictions and Listing in the 2nd Lifting Period of Reserved Granted Part under the 2021 Restricted Stocks Incentive Plan
May 26, 2025
Announcement on Attending the 2025 Online Collective Reception Day for Investors of Listed Companies in Jiangxi Jurisdiction
May 16, 2025
Board of Supervisors' Remarks on Publicity of and Verification Opinions on List of Incentive Objects Initially Granted in the 2nd Restricted Stock Incentive Plan
May 9, 2025
Notice on Convening the 2024 Annual General Meeting
April 25, 2025
Announcement on Obtaining Approval for Phase II Restricted Stock Incentive Plan
April 23, 2025
Announcement on Progress of Controlling Shareholder's Share Increase Plan
April 21, 2025
Indicative Announcement on Publication of 2024 Annual Performance Announcement by Indirect Holding Company China Resources Pharmaceutical Group Limited of Controlling Shareholder
March 26, 2025
Announcement on Using Idle Self-owned Funds to Purchase Wealth Management Products
March 19, 2025
Announcement on Preliminary Earnings Estimate for 2024
January 24, 2025
Summary Announcement on Phase II Restricted Stock Incentive Plan (Revised Draft)
January 1, 2025